Senior Director, GU Oncology Medical & Scientific Affairs
Telix Pharmaceuticals
Aimal Ahmed is a physician who has been in pharmaceutical drug development for 21 years, the last 15 of which have focused on developing drugs that target prostate cancer. Dr. Ahmed has contributed to the development of Xtandi, Pluvicto and he is now part of the medical team at Telix Pharma US, developing a new radioligand therapy for patients with prostate cancer.